Species | SARS-CoV-2 | ||||
Protein Construction |
Expressed with the mutations of Q52R, del 69-70, E484K, Q677H, D614G.
|
||||
Purity | > 90% as analyzed by SDS-PAGE | ||||
Endotoxin Level | < 0.2 EU/μg of protein by gel clotting method | ||||
Biological Activity | This protein is validated to bind with human ACE2 in functional ELISA assay. | ||||
Expression System | CHO | ||||
Theoretical Molecular Weight | 75.7 kDa | ||||
Formulation | Supplied as a solution in PBS, pH 7.4. | ||||
Concentration | Please refer to the COA for the specific lot. | ||||
Storage & Stability | Upon receiving, this product remains stable for up to 6 months at -20°C or below. Please avoid repeated freeze-thaw cycles. |
Target Background | SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. The new variant B.1.525 was first detected by genome sequence in mid-December in Nigeria but was also quickly found in cases in the United Kingdom, France, and elsewhere. The mutation of B.1.525 may increase transmissibility, virulence, and immune escape, the amino acid substitutions Q52R, E484K, Q677H, D614G are located in the spike protein with the deletions at positions 69-70. |
Synonyms | B.1.525; VUI-21FEB-03; VUI-202102/03; UK1188; Nigerian variant NB.1.525; Eta variant |
References |
1. A New Covid-19 Variant From Nigeria Raises Increased Concerns For Containment And Vaccination. 2. Variants of concern or under investigation: data up to 21 April 2021. 3. B.1.525. |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
For more documents, please visit "Technical Support".